Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 7/20 | 0.47 |
| ▸ | CDC25B | P30305 | 7/20 | 0.47 |
| ▸ | CDC25C | P30307 | 6/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7197063 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL6238772 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL6237311 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL10908238 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL10663018 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL6238660 | 0.92 | CDC25A (0.59) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL6486737 | 0.90 | CDC25A (0.41) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL23581852 | 0.89 | CDC25A (0.56) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL8944601 | 0.86 | CDC25A (0.49) | CDC25ACDC25BCDC25CMAPTTDP1 | |
| SCHEMBL15268000 | 0.83 | CDC25A (0.40) | CDC25ACDC25BCDC25CMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467694-B1 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2467694-B1 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS GMBH (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-8658109-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658109-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658109-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130344489-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8460944-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8460944-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8460944-B2 | Use of a bis-maleic anhydride cross-linking agent for fixation of a cell or tissue sample | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2467694-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | Roche Diagnostics GmbH (DE) | 2012-06-27 | — | — | EP | disclosed |
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011020612-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020612-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | ROCHE DIAGNOSTICS GMBH (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149019-A1 | USE OF A BIS-MALEIC ANHYDRIDE CROSS-LINKING AGENT FOR FIXATION OF A CELL OR TISSUE SAMPLE | CA3, CA1, MTCL3 | CDC25A 3037/4885CDC25B 2552/4885CDC25C 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.